Reviews/Targeted Therapy Prostate Cancer/PARP plus androgen receptor inhibitor combination in metastatic castration-resistant prostate cancer
PARP · PC-PARP-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Three large phase 3 trials each paired a PARP inhibitor with an androgen-receptor drug and measured how long patients went before their cancer grew on imaging. In patients whose tumours carried DNA-repair (HRR) gene faults, all three trials showed the combination delayed progression, and a smaller fourth trial [13] pointed the same way. In the broader group of patients not selected by gene status, two of the three trials [2][10] still showed a benefit, but the third [8] stopped its gene-normal arm early because the combination was not working there. The panel treated the claim as satisfied because it allows either the gene-selected group or the unselected group, and the gene-selected benefit is seen everywhere. The main reservations are that the gene-normal benefit is inconsistent, that the measured endpoint is progression on scans rather than how long patients live, and that several reports are conference abstracts.
In HRR-altered disease the radiographic progression-free survival benefit is consistent across all three named trials: TALAPRO-2 reports HR 0.46 in HRR-deficient patients [2] and HR 0.45 [9] / 0.468 [3] in the dedicated cohort, MAGNITUDE reports HR 0.73 in the full HRR+ cohort and 0.53 in BRCA1/2 [8], and PROpel reports HR 0.54 in HRR-mutated patients [10]. For molecularly unselected patients, TALAPRO-2 shows an all-comer HR 0.63 [2] and PROpel an HR 0.66 irrespective of HRR status [10], confirmed by blinded review (HR 0.61) [10]. The smaller randomized phase 2 BRCAAway [13] independently finds the combination (median PFS 39 months) exceeds abiraterone (8.6 months) or olaparib (14 months) alone. MAGNITUDE, by contrast, declared futility in its HRR-negative cohort [8]. The contested point: The division is the 'unselected' population: PROpel and TALAPRO-2 show an all-comer rPFS benefit [2][10] while MAGNITUDE stopped its HRR-negative arm for futility [8]. The non-selected benefit is also smaller than the HRR-altered benefit (PROpel HRR- HR 0.76; TALAPRO-2 HRR-non-deficient HR 0.70) [10][2] and comes with added toxicity such as anemia [2][10].
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim's 'unselected' limb is directly contradicted by MAGNITUDE [8], where the HRR-negative cohort was stopped for futility — the combination does not improve rPFS in all molecularly unselected patients across trials.
rPFS is a surrogate endpoint; a radiographic-PFS gain need not translate to survival, and MAGNITUDE's HRR- futility shows rPFS benefit is not guaranteed outside HRR-altered disease.
Where it remains uncertain. MAGNITUDE declared futility in its HRR-negative cohort [8], so the combination does not improve rPFS in every molecularly unselected population, and the unselected benefit where present is modest [10].
Aleatory
Overall survival was immature at several analyses (TALAPRO-2 all-comers HR 0.89 [2]; HRR-deficient OS HR 0.69 [9]; PROpel OS trend HR 0.81/0.86 [10][11]), so random variation still governs the survival readout.
Epistemic
MAGNITUDE declared futility in HRR- [8] while PROpel and TALAPRO-2 report HRR- benefit (HR 0.76 / 0.70) [10][2]; the corpus does not reconcile why the unselected effect differs by trial.
Inferential
The claim and most entries report radiographic PFS, a surrogate; inferring durable clinical benefit requires a step the corpus only partly supports, with mature OS reached mainly in HRR-deficient TALAPRO-2 (OS HR 0.622) [3].
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows the combination improves rPFS in molecularly unselected (all-comer) mCRPC and in both HRR strata — the core of the claim.
“Median ibPFS by BICR was significantly improved in the TALA + ENZA vs PBO + ENZA arm (not reached vs 21.9 months, respectively; HR, 0.63; 95% CI, 0.51–0.78; P< 0.001). ibPFS was significantly improved in HRR-deficient (HR, 0.46; 95% CI, 0.30–0.70; P< 0.001), HRR-non-deficient or unknown (HR, 0.70; 95% CI, 0.54–0.89; P= 0.004)”
Panel auditInternal validity: high · scope of inference: First-line mildly/asymptomatic mCRPC regardless of HRR status; talazoparib plus enzalutamide vs enzalutamide.Key limitations: conference abstract · OS immature · higher grade 3-4 toxicity in combination arm
Durable, updated rPFS benefit in the HRR-deficient cohort, now alongside a significant OS benefit.
“Updated rPFS data were consistent with the primary analysis, favoring the TALA + ENZA vs PBO + ENZA arm (HR, 0.468; 95% CI, 0.359–0.612; P <0.0001); median rPFS, 30.7 vs 12.3 months, respectively.”
Panel auditInternal validity: high · scope of inference: First-line HRR-deficient mCRPC; talazoparib plus enzalutamide vs enzalutamide.Key limitations: conference abstract · rPFS update is descriptive · HRR-deficient cohort only
Third named trial confirming rPFS benefit in HRR-altered mCRPC; note the companion HRR- futility bounds the 'unselected' limb.
“In the overall HRR+ cohort, rPFS was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.5 v 13.7 months; HR, 0.73; 95% CI, 0.56 to 0.96; P = .022).”
Panel auditInternal validity: high · scope of inference: First-line mCRPC with or without HRR alterations; niraparib plus abiraterone vs abiraterone.Key limitations: futility declared in HRR- cohort · benefit in HRR+ driven by BRCA1/2 · conflicts with claim's unselected benefit
3 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, independent phase 3 rPFS benefit across the three named combination trials in HRR-altered disease, with the unselected limb supported in two of three, warrants Established just below the ceiling given MAGNITUDE's HRR- futility and surrogate-endpoint caveats.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Unselected-population discordance. PROpel and TALAPRO-2 show all-comer rPFS benefit [2][10] while MAGNITUDE's HRR- arm was futile [8]; the claim's 'unselected' clause hinges on resolving this. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective trial or pooled individual-patient analysis stratified by validated HRR status comparing the combinations in confirmed HRR-negative patients.
Open question: Does the combination improve rPFS in rigorously confirmed HRR-negative mCRPC, or is the all-comer signal driven by undetected HRR-altered patients? Why it is still open: MAGNITUDE reports HRR- futility [8] whereas PROpel and TALAPRO-2 report HRR- benefit (HR 0.76 / 0.70) [10][2], and the corpus does not reconcile them.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19